Point-of-care testing for prostate cancer diagnosis

This presentation describes the potential of using a new fully automated QCM biosensor and a commercial SPR biosensor for the detection of PSA, a biomarker for prostate cancer. Initially a new buffer was formulated to eliminate 98% of the non-specific human serum protein binding to the sensors. Obtained results indicate that both instruments can be used for the fast and easy detection of PSA (0.29-150 ng/ml) in serum.